Peptide Therapeutic Deal Benchmarks in Rare Disease

Peptide Therapeutic therapies in rare disease have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 peptide therapeutic asset in rare disease is $416M, with total deal values reaching $2.2B. Development milestones average $402M, while regulatory milestones contribute $457M.

The rare disease peptide therapeutic landscape is characterized by limited competitive intensity per indication but growing platform competition. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.